|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 12 (December 15), 1997:
pp. 5002-5012
AC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
By
Amy H. Yin,
Sheri Miraglia,
Esmail D. Zanjani,
Graca Almeida-Porada,
Makio Ogawa,
Anne G. Leary,
Johanna Olweus,
John Kearney, and
David W. Buck
From AmCell Corp, Sunnyvale, CA; Veterans Administration Medical Center, University of Nevada, Reno, NV; Ralph H. Johnson Department of Veterans Affairs Medical Center and the Department of Medicine, Medical University of South Carolina, Charleston, SC; Becton Dickinson Immunocytometry Systems, San Jose, CA; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL.
 |
ABSTRACT |
AC133 is one of a new panel of murine hybridoma lines producing monoclonal IgG antibodies (mAbs) to a novel stem cell glycoprotein antigen with a molecular weight of 120 kD. AC133 antigen is selectively expressed on CD34bright hematopoietic stem and progenitor cells (progenitors) derived from human fetal liver and bone marrow, and blood. It is not detectable on other blood cells, cultured human umbilical vein endothelial cells (HUVECs), fibroblast cell lines, or the myeloid leukemia cell line KG1a by standard flow cytometric procedures. All of the noncommitted CD34+ cell population, as well as the majority of CD34+ cells committed to the granulocytic/monocytic pathway, are stained with AC133 antibody. In vitro clonogenicity assays have demonstrated that the CD34+AC133+ double-positive population from adult bone marrow contains the majority of the CFU-GM, a proportion of the CFU-Mix, and a minor population of BFU-E. The CD34dim and AC133- population has been shown to contain the remaining progenitor cells. AC133-selected cells engraft successfully in a fetal sheep transplantation model, and human cells harvested from chimeric fetal sheep bone marrow have been shown to successfully engraft secondary recipients, providing evidence for the long-term repopulating potential of AC133+ cells. A cDNA coding for AC133 antigen has been isolated, which codes for a polypeptide consisting of 865 amino acids (aa) with a predicted size of 97 kD. This antigen is modeled as a 5-transmembrane molecule, a structure that is novel among known cell surface structures. AC133 antibody provides an alternative to CD34 for the selection and characterization of cells necessary for both short- and long-term engraftment, in transplant situations, for studies of ex vivo expansion strategies, and for gene therapy.
| |
INTRODUCTION |
EFFICIENT SELECTION of hematopoietic stem and progenitor cells is important for both experimental investigation and the clinical strategies of stem cell transplantation and gene therapy.1 Functionally, isolated progenitors may permit study of the lineage commitment process and the capacity for ex vivo expansion.2 Transplantation of enriched bone marrow or peripheral blood progenitors devoid of T lymphocytes may minimize serious complications of bone marrow allografts such as graft-versus-host disease, and tumor cell purging may be crucial to reducing tumor recurrence in autologous transplantation. The use of growth factors in ex vivo expansion of progenitor subsets could provide the next generation of cellular therapeutics for a variety of malignant and inherited diseases.2-4 Monoclonal antibodies (MoAbs) to cell surface antigens are now routinely used for identification and subsequent isolation of subsets of progenitors, and have been useful for elucidation of receptor/ligand interactions involving progenitors and humoral or cellular regulatory elements.5-7
Bone marrow- and blood-derived progenitors share expression of a great many surface markers with other hematopoietic cells, and they typically constitute less than 1% of normal bone marrow and 0.5% of peripheral blood.8 Unfortunately, direct conventional strategies to develop novel antibodies specific for progenitors have been difficult due to the relative paucity of stem cells for immunization and screening purposes, and the immunodominance of class II and other stem cell antigens, which dominate the immune response when using standard immunization procedures.
The marker of choice in progenitor selection strategies is CD34,9 and over the past decade, the use of CD34 as a progenitor surface marker has resulted in a rapid appearance of more sophisticated purification techniques and clinical trials in the field of hematopoiesis.1,10,11 CD34 is a stage-specific antigen associated with hematopoietic stem and progenitor cells that is also expressed on small-vessel endothelial cells9,12 and embryonic fibroblasts.13 CD34 antigen density is highest on early progenitors, and the density decreases progressively as cells mature.14 Fully differentiated hematopoietic cells are CD34-. Cells described as early multipotential CFU-Mix, CFU-blast, and long-term culture-initiating cells appear as lymphocyte-like cells and express high amounts of CD34 antigen.9,15,16 The CD34bright population includes cells with features of long-term B-cell lymphopoiesis and myelopoiesis in vitro, as well as mediating T, B, myelomonocytic, and megakaryocytic repopulation in vivo, while the CD34dim population contains lineage-committed progenitors, and these cells have no ability to provide long-term hematopoietic activity in vitro and in vivo.17,18 The CD34bright population containing primitive stem cell activity is therefore the target population for study of progenitor reconstitutive and self-renewal abilities. However, only an arbitrary distinction between CD34bright and CD34dim subsets can be made on the basis of CD34 expression alone. CD38, CD71, CD50, HLA-DR, CD90, TIE, CD117, and other markers18-24 have been proposed as additional tools to further enrich the CD34+ population for long-term engrafting cells. The consensus phenotype of primitive hematopoietic stem cells is CD34bright, CD38dim/-, HLA-DRdim/-, CD90+, CD117+, lineage-, and rhodamine 123lo.24-27
In this report, we describe an immunization and screening procedure that has allowed the production of a novel MoAb, AC133. AC133 identifies a structurally novel 5-transmembrane antigen with expression restricted to CD34bright progenitor populations derived from blood and bone marrow. In contrast to CD34, AC133 does not react to HUVECs, the KG1a cell line, or fibroblasts. AC133 defines a population of immature/primitive and GM-committed cells that can subsequently be isolated by AC133 antibody using fluorescence or magnetic-activated cell sorting. Our observations show that AC133 defines a desirable population for experimental study of hematopoiesis and ex vivo expansion of progenitors. In providing a source of primitive stem cells, together with progenitor cells committed to the granulomonocytic maturation pathway, AC133 may have an important role in stem cell selection for transplantation.
| |
MATERIALS AND METHODS |
Fetal tissues and cord blood were obtained from Advanced Bioscience Resources Inc, (Alameda, CA), a nonprofit corporation that provides tissue in compliance with state and federal laws. Peripheral blood and cytokine-mobilized leukapheresis products were from Stanford Medical School Blood Center (Palo Alto, CA). Bone marrow cells were aspirated from the posterior iliac crest of consenting healthy adult donors following guidelines approved by the Institutional Review Board for Human Research, Medical University of South Carolina, the Ralph H. Johnson Department of Veterans Affairs Medical Center, University of Nevada, Reno, and Stem Cell Laboratories, Division of Hematology and Oncology, University of California, San Diego, CA.
Mononuclear Cell Preparation
Peripheral blood or cord blood was diluted with phosphate-buffered saline (PBS), pH 7.4 (Sigma, St Louis, MO) and centrifuged over Histopaque-1077 (Sigma) for 30 minutes at 400g.28 Mononuclear cells recovered from the interface were washed and stored in liquid nitrogen if not used immediately.
Fetal Liver Preparation
Second-trimester fetal livers were mechanically dissociated in PBS, pH 7.4, containing 5 mmol/L EDTA, 0.5% bovine serum albumin (BSA), and 0.05% sodium azide (Sigma). The cell suspension was filtered sequentially through a Cellector Tissue Sieve (VWR, San Diego, CA) and 70-µm nylon mesh. Red blood cells, nucleated red blood cells, and mononuclear cells were separated by Histopaque-1077 density sedimentation. The CD34-rich fragment was collected from the interface. Cells were then washed and stored in liquid nitrogen for further use. Normally, 108 to 109 cells were harvested from one specimen, and the proportion of intact CD34+ cells obtained was between 5% and 15%.
Fetal and Adult Bone Marrow Preparation
For phenotypic analysis, fetal bone marrow was obtained from aborted fetuses of 17 to 22 weeks' gestation. Marrow suspension was prepared by flushing intramedullary cavities of upper- and lower-extremity bones with PBS, pH 7.4, containing 5 mmol/L EDTA, 0.5% BSA, and 0.05% sodium azide. The cells were pelleted and resuspended in the same buffer. Adult bone marrow and cell suspensions from fetal bone marrow were diluted 10-fold in buffer containing 0.17 mmol/L NH4Cl, 10 mmol/L KHCO3 , and 0.1 mmol/L tetrasodium EDTA in double-distilled H2O (pH 7.2, 20°C) to lyse the mature red blood cells. After 5 minutes of lysing, cells were centrifuged, washed, and passed through a 70-µm nylon filter (Becton Dickinson Immunocytometry Systems [BDIS], San Jose, CA) for subsequent staining.
Adult bone marrow for in vitro colony assays or in vivo studies was diluted with an equal volume of PBS without calcium or magnesium (PBS- ) and centrifuged over Accupaque (1.086 g/mL; Accurate Chemical and Scientific Corp, Westbury, NY) for 30 minutes at room temperature at 450g. The cells at the interface were washed three times with PBS- and resuspended in  -medium (-modification of Eagle's medium; ICN, Aurora, OH) containing 10% fetal bovine serum (Intergen, Purchase, NY) for overnight storage at 4°C. Before analysis, cells were resuspended in PBS- containing 2% human AB serum, 0.1 mg/mL DNase (Sigma), and 0.1% sodium azide.
CD34+ Cell Purification
For immunization and FACS analysis, CD34+ cells were enriched from fetal liver preparations, fetal and adult bone marrow, cord blood, peripheral blood, or mobilized leukapheresis product. Cells from these sources were first prepared with Histopaque-1077 density gradient centrifugation. Mononuclear cells were then incubated with CD34 (QBEnd10)-conjugated magnetic microbeads (AmCell Corp, Sunnyvale, CA) and processed through a MACS magnetic separation column (Miltenyi Biotec, Bergisch Gladbach, Germany) to obtain purified CD34+ cells.29 For higher purity of CD34+ cells, a second column run was used. Purity of isolated CD34+ cells was generally greater than 90%, and cell viability as evaluated by propidium iodide exclusion was always higher than 95%.
Antibody Production
Immunization.
For the AC133 hybridoma, 6-week-old female New Zealand Black (NZB) mice (Simonsen Laboratories, Gilroy, CA) were inoculated with human CD34+ cells under anesthesia on days 0, 3, 6, 9, 13, 17, and 20 in the right hand footpad, and peripheral blood mononuclear cells in the left hand footpad on days -3, 0, 3, 6, 9, 13, 17, and 20. CD34+ cells were immunomagnetically selected (QBEnd10 microbeads; AmCell Corp, Sunnyvale, CA) from a leukapheresis pack prepared from a cytokine-mobilized donor. Both cell types were incubated with 1:100 phytohemagglutinin (PHA) (GIBCO/BRL, Gaithersburg, MD) for 10 minutes before injection. Approximately 3 to 5 × 105 cells in 0.03 mL PBS, pH 7.4, were inoculated per footpad. For AC133-like hybridomas, 6-week-old female Balb/c mice (Simonsen) were immunized with WERI-Rb-1 cells. A total of seven injections of 5 × 105 cells were given via each footpad twice weekly.
Fusion.
On day 21, right hand popliteal lymph nodes from the CD34 cell injection site of NZB mice or both popliteal nodes from WERI-Rb-1-injected Balb/c mice were removed. A lymphocyte suspension was prepared and fused to SP2/0 Ag14 myeloma cells using a modification of the method described by Köhler and Milstein.30 Fused cells were plated on 10 96-well plates in DMEM supplemented with 20% fetal bovine serum (FBS), 2 mmol/L L-glutamine, 15 mmol/L HEPES, 10-4 mmol/L hypoxanthine, and 2 µg/mL azaserine31 (FCS from HyClone Laboratories Inc, Logan, UT; other reagents from Sigma), and placed in a 37°C incubator with 9% CO2 .
Primary screening and subcloning.
Hybridoma supernatants were screened on fetal liver cell preparations using two-color flow cytometric analysis. Binding of secreted mouse Ig from supernatants to the fetal liver cells was traced with phycoerythrin (PE)-conjugated rat antimouse IgG1 and IgG2a+2b (BDIS), and counterstaining with fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD34 (HPCA-2, BDIS; QBEnd10, AmCell Corp). Dead cells in the fetal liver preparation were excluded from analysis by propidium iodide staining.32 CD38PE and HLA-DRFITC (PharMingen, San Diego, CA) were used for FACScan compensation. All selected antibodies used later for this study were derived from cells subcloned by limiting dilution. The isotype of new antibodies was determined by the ISOTYPE Ab-STAT Kit (SangStat Medical Corp, Palo Alto, CA) or by FACS analysis using rat anti-mouse isotype fluorescent conjugates (BDIS).
Antibody Purification and Conjugation
Pure AC133 or AC133-like antibodies were prepared from hollow-fiber (Cellmax QUAD Artificial Capillary System; Cellco Inc, Germantown, MD) cultures or from ascites fluid by protein A chromatography.33 FITC and PE conjugates were prepared using standard procedures.34,35 AC133 magnetic bead conjugates were obtained from Miltenyi Biotec.
Cell Lines and Activation
Cell lines used for this study were obtained from the ATCC (Rockville, MD) and maintained in DMEM with 10% FBS, 2 mmol/L-glutamine, and 15 mmol/L HEPES in a 9% CO2 atmosphere. HUVECs were from Clonetics (San Diego, CA), and NT-2 and hNT neurons were kindly provided by Dr M. McGrogan (Layton BioSciences, Gilroy, CA). Anchorage-dependent cells were removed from the flasks by Trypsin-EDTA digestion (GIBCO/BRL). For activation, 1:100 PHA was added to aseptically prepared peripheral blood mononuclear cells in culture medium and placed in a 37°C humidified incubator with 9% CO2 . Cell lines KG1a, K562, HEL92.1.7, Jurkat, Daudi, HPB-ALL, SK-N-MC, SK-N-SH, H4, 134H, 8402, Y79.1, and WERI-Rb-1 were activated with 1 ng/mL phorbol myristate acetate ([PMA]-GIBCO/BRL). Activated cells were harvested at 24-, 48-, 72-, 96-, and 120-hour intervals and washed with PBS before FACS analysis.
Cell Staining
To minimize nonspecific antibody binding, cells were preincubated with PBS containing 0.5% human  -globulin (Sigma). For indirect immunofluorescence staining, nucleated cells from bone marrow, cord blood, or fetal liver were incubated with an unlabeled MoAb, washed twice in PBS-FCS, and stained with fluorochrome-conjugated secondary antibodies. Before additional labeling with fluorochrome-conjugated MoAbs, the cells were washed twice and incubated for 20 minutes with 30% normal mouse serum to block remaining binding sites for antimouse IgG. All incubation steps were performed on ice for 25 minutes. Immunostained cells were either kept on ice and analyzed immediately by flow cytometry or fixed in 0.5% paraformaldehyde and analyzed within 48 hours.
Flow Cytometric Analysis
One-, two-, three-, or four-color FACS analysis was used for AC133 antibody screening, determination of AC133 expression on cell lines, AC133+ cell phenotyping, and stem/progenitor cell evaluation after magnetic selection. CD90PE (Thy-1) was obtained from Pharmingen. Anti-Flt3 MoAb SF 1.340 and CD117 MoAb 104D2 were obtained from the Sixth International Workshop on Leukocyte Differentiation Antigens. MoAbs used to discriminate between noncommitted and various lineage-committed progenitor cells included CD34 (HPCA-2), CD38 (Leu-17), CD19 (SJ25C1), CD71 (transferrin receptor) (all from BDIS), CD50 (140-11; kindly provided by Dr Ramon Vilella, Servei d'Immunologia, Hospital Clinic, Barcelona, Spain), and CD64 (M22; MedaRex Inc, Annandale, NJ). The mAbs were conjugated to FITC, PE, peridinin chlorophyll protein (PerCP), or allophycocyanin (APC). Fluorochrome conjugates that are not listed in the BDIS catalog were made through the BDIS custom conjugation program. Isotype control mouse MoAbs included anti-keyhole limpet hemocyanin (IgG1; BDIS) and NC2 (IgG1; Fifth International Workshop on Leukocyte Differentiation Antigens). Polyclonal PE-conjugated F(ab' )2 goat anti-mouse IgG heavy + light chain was purchased from Jackson ImmunoResearch (West Grove, PA). Normal mouse serum was from Caltag Laboratories (South San Francisco, CA).
For phenotypic analysis, immunostained cells were analyzed using an experimental high-sensitivity flow cytometer designed by Dr Robert Hoffman at BDIS. This flow cytometer is equipped with three lasers: a 488-nm argon ion laser (15 mW) for excitation of PerCP and FITC, a 633-nm helium-neon laser (10 mW) for excitation of APC, and a 532-nm YAG laser (20 mW) for excitation of PE. The 532-nm excitation of PE yields six times the signal to noise ratio obtained with 488-nm excitation (not shown). For each sample, 10,000 to 50,000 events were acquired in list mode with Cell Quest software (BDIS). Forward light scatter, orthogonal light scatter, and four fluorescence signals were determined for each cell, and the listmode data files were analyzed on a Macintosh computer with Paint-A-GatePRO (BDIS).
Colony Assay
Adult bone marrow cells were stained with PE-conjugated AC133 antibody at a concentration of 200 ng/106 cells in a volume of 100 µL and with FITC-conjugated CD34 antibody7 at a concentration of 2 µg/106 cells in 100 µL for 30 minutes at 4°C. Propidium iodide was added to the final wash as an indicator of nonviable cells. A BDIS FACS Vantage was used to analyze and sort bone marrow mononuclear cells into fractions of CD34+, CD34+/AC133+, and CD34+/AC133-.
Clonal cell cultures were performed in 35-mm culture dishes using serum-free conditions.7,36 One milliliter of the culture mixture contained 500 sorted cells, 2% deionized crystallized BSA, 10 µg/mL soybean lecithin, 6 µg/mL cholesterol, 1 × 10-7 mol/L sodium selenite, 300 µg/mL human transferrin, 10 µg/mL insulin (reagents from Sigma), and 1.2% 1,500-centipoise methycellulose (Shinetsu Chemical, Tokyo, Japan).
The source of recombinant human cytokines was as previously described.7 Concentrations of the cytokines were interleukin-3 (IL-3) 100 U/mL, stem cell factor (Steel factor, kit ligand) 100 ng/mL, thrombopoietin (TPO) 100 ng/mL, IL-6 100 ng/mL, and erythropoietin (EPO) 2 U/mL. Cultures were incubated at 37°C in a humidified atmosphere of 5% CO2 , 5% O2 , and 90% N2 . Colonies were identified on day 14 of incubation, on an inverted microscope using the criteria described previously.37
Preliminary In Vivo Analysis
After two washes with PBS, pH 7.4, containing 0.5% BSA and 5 mmol/L EDTA, bone marrow mononuclear cells were incubated with AC133-conjugated magnetic beads (Miltenyi Biotec) for 30 minutes at 4°C and passed through a VS column in the magnetic field of a VarioMACS Apparatus (Miltenyi Biotec). To obtain a higher purity of CD34bright cells, eluted AC133 cells were recaptured on a second VS column. Recovered bone marrow cells were evaluated by FACS analysis with CD34PE (HPCA-2 ; BDIS) against CD45FITC, CD15FITC, and Glycophorin-A FITC (Pharmingen). Ninety-five percent of AC133 cells obtained from bone marrow magnetic separation were CD34bright. AC133-selected cells were transplanted into primary preimmune fetal sheep (earlier than 65 gestation days; term, 145 days) recipients using the amniotic bubble technique.38 Five fetuses received a single intraperitoneal injection of 1.5 × 105 AC133-purified cells. All recipients survived the procedure. One fetus was killed at 60 days posttransplantation (ie, 120 days gestation, 25 days before birth) and evaluated for human donor cell activity by flow cytometry. The remaining animals were carried to term. These lambs were evaluated soon after birth and at intervals thereafter. For transplantation of secondary recipients, human CD45+ cells were isolated from the marrow of a primary chimeric recipient by immune adherence "panning" and transplanted into preimmune fetal sheep.39 Each of four fetuses received 6 × 104 CD45+ cells isolated from the marrow of a primary recipient made chimeric with AC133-purified cells. Donor cell engraftment and expression were determined by flow cytometry and karyotyping of colonies derived from hematopoietic progenitors (CFU-Mix, CFU-GM, and BFU-E) as previously described.40
| |
RESULTS |
Antibody Production and Screening
The contralateral immunization of NZB mouse popliteal lymph node cells with purified progenitors has allowed the production of an IgG1-secreting hybrid culture, 5F3, which stained only the CD34bright subset of a fetal liver preparation (Fig 1). This hybridoma was subcloned by limiting dilution and renamed AC133. AC133 was of immediate interest in that it was not reactive to unfractionated peripheral blood mononuclear cells (PBMCs), granulocytes, platelets, fibroblasts, cultured HUVECs, or various CD34-expressing cell lines such as KG-1, KG-1a, or 84029 (Table 1). By FACS analysis, AC133 specifically stained CD34bright cells in human fetal livers (n = 27; mean, 29.88% of CD34+ cells) and bone marrow (n = 3; mean, 31.6%), adult bone marrow (n = 2; mean, 70%), cord blood (n = 2; mean, 35.13%), and leukapheresis products from cytokine-mobilized donors (n = 3; mean, 54.9%) (Fig 1). Staining of PHA-activated PBMCs was negative (data not shown). AC133 antigen expression by FACS analysis of a large panel of hematopoietic and nonhematopoietic cell lines was uniformly negative, with the exception of two human retinoblastoma cell lines, Y79.1 and WERI-Rb-1, and one teratocarcinoma-derived cell line, NT2 (Table 1 and Fig 2.) These NT2 precursor cells differentiate into postmitotic cells with properties of central nervous system neurons in vitro by retinoic acid induction.55 hNT neurons derived from the NT2 cell line were found to have downregulated AC133 antigen expression to undetectable levels (not shown). While AC133 antigen expression levels were low on Y79.1 cells, they were approximately 10-fold higher on WERI-Rb-1 cells. The 24-hour PMA activation of Y79.1 resulted in upregulation of AC133 antigen expression, but no upregulation was seen with the WERI-Rb-1 cell line. PMA activation of a panel of cell lines for 24 to 96 hours did not induce AC133 antigen expression (Table 1). Retinoblastoma cell line expression led us to examine AC133 expression on other cell lines of neural origin; however, AC133 was found to be nonreactive with SK-N-SH, SK-N-MC, or IMR32, three neuroblastoma cell lines, with H4, a human neuroglioma cell line, or with 134H, a glioblastoma cell line (Table 1). Baboon bone marrow cells (kindly provided by Dr Jonathon Allen, Southwest Foundation for BioMedical Research, San Antonio, TX) did not express the AC133 antigen (data not shown).
View larger version (28K):
[in this window]
[in a new window]
| Fig 1.
AC133 expression on fetal liver cells. Fetal liver mononuclear cells were stained with AC133PE (vertical axis) and CD34FITC (horizontal axis) as described. CD34bright/AC133+ cells are seen in region R2. The gates R1 and R2 are representative of those used in selection of bone marrow CD34/AC133 subpopulations for in vitro colony assays.
|
|
View larger version (17K):
[in this window]
[in a new window]
| Fig 2.
Flow cytometric staining of (A) retinoblastoma cell line WERI-Rb-1 and (B) teratocarcinoma cell line NT2 with PE-conjugated antibodies. Solid line, IgG1 control; dashed line, QBEnd10 (CD34); bold line, AC133. All three antibodies were isotype IgG1.
|
|
The WERI-Rb-1 cell line that expressed high levels of AC133 antigen was used as immunogen in two further immunizations to produce a panel of antibodies to the AC133 antigen. Balb-c mice were immunized via the footpad with WERI-Rb-1 cells, and two separate fusions of popliteal lymph node cells from these animals resulted in a number of new hybridomas that secreted AC133-like antibodies (Table 2). Specificity of these new antibodies was confirmed by two- or three-color FACS analysis, cross-blocking studies, immunoprecipitation, and/or by reactivity with AC133-transfected COS cells.41 Cross-blocking studies using an excess (5 µg) of unlabeled antibody to compete with the binding of AC141PE conjugate to the AC133+ cell line WERI-Rb-1 indicates that at least two and maybe three spatially unrelated epitopes are recognized by the panel of antibodies in Table 2.
Phenotyping Studies
Phenotyping of AC133+ cells was accomplished using multicolor FACS analysis with a panel of conjugated antibodies directed to leukocyte surface structures known to be expressed on human hematopoietic stem, progenitor, or lineage-committed progenitor cells. Typically, AC133 stained 20% to 60% of all CD34+ cells derived from fetal liver and bone marrow, adult bone marrow, cord blood, and peripheral blood. Only CD34+ cells from all of these tissue sources were AC133+. Fetal bone marrow (FBM) cells were stained with AC133 and also CD38, CD50, CD64, CD71, and CD19 to allow identification of noncommitted and various lineage-committed progenitor cells (Fig 3). AC133 did not stain above isotype control levels on CD34negative cells (not shown). Figure 3B through E represent CD34+ cells gated from region R1 in Fig 3A, and 26% to 37% of CD34+ cells were AC133+ (n = 3). Noncommitted progenitor cells were identified as CD34brightCD38-CD50+ cells,17,19,42 and were among the CD34+ cells showing the brightest staining with AC133 (Fig 3B, violet dots). In contrast, only a subset of lymphoid-committed progenitors, identified as CD34+CD19+ cells,43 stained with levels above the isotype control (Fig 3C, blue dots). Granulomonocytic-committed progenitor cells (CD34+CD64+, green dots in Fig 3D) showed decreasing staining with AC133 with increasing levels of CD64 expression, indicating downregulation of the AC133-binding molecule with granulomonocytic differentiation.26,44 However, the mean fluorescence intensity (MFI) for this subset was higher than the MFI for the lymphoid-committed (Fig 3C) and erythroid-committed (red dots, Fig 3E) progenitors. The erythroid-committed progenitor cells (CD34brightCD71brightCD64- )26,45 stained with AC133 only slightly above isotype control levels. The staining pattern of adult bone marrow (ABM) CD34+ and CD34- cells with AC133 closely resembled that shown for FBM cells (Fig 3). However, a larger fraction of CD34+ ABM cells stained positively with AC133 (64% to 76%, n = 2) as compared with FBM cells. Figure 4 furthermore shows that when labeling with CD34 and AC133, CD117 (anti-SCF-R), or anti-Flt3, respectively, AC133 fluorescence shows the closest positive correlation with CD34 fluorescence. Both Flt3 (Fig 4B) and CD117 (Fig 4C) were expressed also on subsets of CD34- cells.
View larger version (48K):
[in this window]
[in a new window]
| Fig 3.
Staining of FBM cells with AC133. Ammonium chloride-lysed FBM cells were labeled with AC133 and goat anti-mouse PE, followed by staining with CD34FITC (A through E) and CD38APC and CD50PerCP (B), or CD19APC (C), or CD64APC and CD71PerCP (D and E). (A) Unfractionated FBM cells. (B through E) Staining of CD34+ cells only, gated from region R1 in A. Noncommitted progenitor cells (CD34hiCD38loCD50+ ) are represented by enlarged violet dots in B, and lymphoid committed progenitors (CD34+CD19+ ) are depicted in blue in C. Granulomonocytic committed progenitors (CD34+CD64+ ) are represented by green dots in D, and erythroid committed progenitors (CD34hiCD71hiCD64- ) are depicted in red in E. Dashed lines represent isotype control levels for each of the colored populations. tOLS, transformed orthogonal light scatter. The results are representative of 3 experiments.
|
|
View larger version (20K):
[in this window]
[in a new window]
| Fig 4.
Staining of ABM cells with AC133, CD117 (SCF-R), or anti-Flt3. Ammonium chloride-lysed ABM cells were labeled with AC133 (A) or anti-Flt3 (SF 1.340, B), or anti-SCF-R (104D2, C) and goat anti-mouse PE, followed by staining with CD34FITC. The results are representative of 2 experiments.
|
|
AC133 cDNA Cloning and Protein Structure
The isolation and sequencing of a novel cDNA encoding the AC133 antigen is described in detail elsewhere.41 Briefly, the cDNA encodes a single open reading frame of 2,595 nucleotides, and predicts an 865-amino acid protein with a MW of 97 kD. The AC133 antigen is modeled as a 5-transmembrane protein with an extracellular N-terminus and a cytoplasmic C-terminus. The structure of the AC133 antigen appears to be novel among known hematopoietic cell surface antigens.46,47 Immunoprecipitation detected AC133 antigen with a molecular weight of 120 kD in PMA-activated Y79.1 and WERI-Rb-1 cells.
In Vitro Colony Assays
Quadruplicate culture dishes were seeded with 500 adult bone marrow cells sorted from regions similar to those depicted in region R1 + R2 (CD34+ ), R1 (CD34+, AC133- or R2 (CD34+, AC133+ ) (Fig 1). There were no AC133+ cells that were negative for CD34. On day 14 of incubation, culture dishes were scored for colony growth as previously described.37 The results shown in Table 3, which is an example of one of three similar experiments, clearly indicate that the majority of CFU-GM are contained in the CD34+/AC133+ fraction, while the majority of BFU-E and CFU-Mix are in the CD34+/AC133- fraction. This finding is surprising, as CFU-Mix have been previously considered to be more primitive and therefore to express a high density of CD34.9
In Vivo Engraftment Studies
Xenogeneic transplantation studies were performed using the fetal sheep model as previously described.38 In this set of experiments, fetal sheep were inoculated with 1.5 × 105 CD34/AC133 double-positive cells. The bone marrow of one member of this group of primary recipients was analyzed for the presence of human cells at 60 days posttransplant, which is approximately 25 days before birth, and these human cells were used to inoculate secondary recipients. Other animals were carried to term and examined at various times after birth using CD45 expression or in vitro colony formation for the presence of human donor cells in bone marrow. The percentage of colonies exhibiting a human karyotype and the percentage of marrow cells expressing the CD45 antigen in these primary recipients are listed in Table 4. The percentage of CD45+ cells in the marrow of primary recipients ranged from 0.7% to 1.7% of total marrow mononuclear cells, and in vitro derived colonies demonstrate the human and multilineage nature of these cells. Only primitive repopulating cells have the ability to engraft in secondary recipients,48 and therefore, human progenitors isolated from secondary recipients must necessarily be derived from primitive stem cells obtained from the primary recipients. The data in Table 5 clearly demonstrate that multilineage cells were identified and isolated from the marrow of secondary recipients harvested at 60 days posttransplant. These cells, 0.1% to 2.14% of total marrow mononuclear cells, were identified as human both by karyotyping and by CD45 antigen expression. Given that human progenitor cells are only minimally stimulated by sheep growth factors49 and considering the relatively small number of cells inoculated (6 × 104 per fetus), the level of engraftment of human progenitor cells in these chimeric sheep marrows can be considered very significant.
View this table:
[in this window]
[in a new window]
|
Table 5.
Relative Distribution of Donor (human) Hematopoietic Progenitors/Cells in Bone Marrow of Secondary Sheep
Recipients at 60 Days Posttransplant
|
|
Phenotypic analysis of AC133+ cells strongly suggested that primitive repopulating stem cells were included within the AC133+/CD34+ population, which was confirmed by the data presented here from bone marrow analysis of sheep made chimeric with human AC133+ cells.
| |
DISCUSSION |
Human hematopoietic stem and progenitor cells share a large number of immunogenic cell surface structures with mature hematopoietic cells.46,47 Molecules such as HLA class I and II,  1 and 2 integrins, CD26, CD31, CD43, CD44, CD45, CD50, CD53, and CD71 are examples of structures expressed on CD34+ cells, and these can dominate the immune response to a level where less immunogenic/novel molecules are not recognized by the host animal. Other investigators have approached this problem with techniques such as subtractive immunization,50,51 where animals are exposed to the tolerizing agent cyclophosphamide to suppress the immune response to immunodominant antigens. Our approach to this problem has been a contralateral footpad immunization procedure in mice, where the left footpad is injected with mature hematopoietic cells that express many of the antigens expressed on progenitors and the right footpad is injected with CD34+ progenitors. This system relies on the ability of antigen-specific lymphocytes to traffic to the site of initial antigenic stimulation. Therefore, in this example, the left footpads of the mice were injected on days -3, 0, 3, 6, 9, 13, 17, and 20 with PBMCs, while the right footpads were injected with purified progenitors on days 0, 3, 6, 9, 13, 17, and 20. Antigen-specific lymphocytes specific for shared antigens were decoyed to the left popliteal lymph node, while lymphocytes draining to the right popliteal node were more likely to respond to less immunogenic and hopefully novel structures. This powerful immunization procedure combined with the utilization of human fetal liver cell populations that provide large numbers of CD34+ progenitors for screening has permitted the recognition of a novel MoAb, AC133, that recognizes only the CD34bright subset of human progenitors. This antibody reacts with only two human retinoblastoma cell lines and a teratocarcinoma cell line from a panel of 46 human cell lines tested. It is of interest that we have not encountered a cultured cell line that is double-positive for both AC133 and CD34. CD34 and AC133 antigens are coexpressed on primitive progenitors and on some leukemias,41 and therefore, both can be considered early antigens. However, the lack of reactivity of AC133 antibody to endothelial cells or fibroblasts, together with the cell line staining data and immunohistology,41 demonstrates that the AC133 antigen is restricted to stem cells and possibly a few other tissues such as retina, pancreatic islet cells, and placenta. While protein expression has not been demonstrated on these last three tissues, ESTs (expressed sequence tags) derived from human tissues such as retina, pancreatic islets, and placenta matching the AC133 gene sequence are present in Genebank.41 Therefore, although progenitor cells coexpress these two early antigens, they appear to share no other known relationship, as the function of either molecule is not known and the expression on other cells and tissues and the degree of antigen glycosylation and protein structure41 are markedly different.
Expression of the AC133 antigen has been shown to be restricted to human progenitors and to a teratocarcinoma cell line, NT2, as well as two retinoblastomas, using FACS analysis of multiple primary and continuous cell lines. The two retinoblastoma lines are composed of neuron-committed cells and are karyotypically abnormal.52 NT2 cells from a human malignant testicular germ cell tumor may contain elements that resemble extraembryonic tissues of the trophoblast, yolk sac, or various embryonic tissues. NT2 cells have been reported to represent a committed neuronal precursor stage of differentiation,53,54 which differentiate to mature neurons on induction with retinoic acid. The differentiated cells, called hNT neurons, lose neuroepithelial markers such as VLA-4 (CD49d) and cytokeratins detected by the antibody CAM-5.2 (A.Y. and D.B., unpublished data, September 1996). AC133 antigen expression is undetectable on hNT neurons, and therefore appears to be a very early antigen, which is rapidly lost during cell differentiation. No sequence similarity with known tyrosine kinase receptor families or with other multiple transmembrane antigens has been found.41
We have shown that AC133 is expressed on a population of stem and progenitor cells that contain all of the CD34bright and CD38- progenitors, as well as the CD34bright cells committed to the granulocytic/monocytic pathway. These cells engraft and home to the bone marrow of fetal sheep in a xenogeneic transplantation model. Moreover, cells harvested from primary sheep recipients successfully engraft secondary recipients, demonstrating the long-term repopulating potential of AC133-derived progenitors. One surprising finding in this series of experiments was that the majority of the CFU-Mix population, which is generally considered to be a primitive population of progenitors, were found in the CD34dim/AC133- fraction. In the murine system, single CD34dim cells have been shown to reconstitute lethally irradiated mice,55 suggesting the possibility that the true stem cell may in fact be CD34- or CD34dim. Whether a similar cell type exists in man will require further study.
While the AC133 antigen has no known ligand or function at this time, we have shown it to have a novel expression pattern and 5-transmembrane structure.41 Downregulation to undetectable levels in mature hematopoietic cells and on terminally differentiated teratocarcinoma cells, as described for growth factor receptors such as fibroblast growth factor receptor,56 may suggest a functionally restricted role for this molecule. Alternatively, the presence of a leucine zipper motif in the second extracellular loop of the AC133 molecule41 may suggest a role in protein-protein interactions, perhaps with bone marrow stromal antigens. The AC133 antigen system that provides all CD34+/CD38- primitive cells, including presumably the SCID repopulating cell57 as well as CFU-GM needed for short-term engraftment,58 may provide an alternative to the widely used CD34 antigen in hematopoietic stem cell manipulations.
| |
FOOTNOTES |
Submitted June 11, 1997;
accepted August 14, 1997.
Supported in part by National Institutes of Health Grants No. A135940, HL52955, HL49042, and DK51427.
Reprint requests to David W. Buck, AmCell Corp, 1190 Bordeaux Dr, Sunnyvale, CA 94089.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
We thank Kerry MaGee and Gary Frenzel for excellent technical assistance, and Michael McGrogan for the generous gift of NT-2 cells and hNT neurons.
| |
REFERENCES |
1.
deWynter EA,
Coutinho LH,
Pei X,
Marsh JCW,
Hows J,
Luft T,
Testa NG:
Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems.
Stem Cells
13:524,
1995[Medline]
[Order article via Infotrieve]
2.
Emerson SG:
Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: The next generation of cellular therapeutics.
Blood
87:3082,
1996[Free Full Text]
3. Haylock DN, To LB, Makino S, Dowse TL, Juttner CA, Simmons PJ: Ex vivo expansion of human hematopoietic progenitors with cytokines, in Levitt D, Mertelsmann R (eds): Hematopoietic Stem Cells, Biology and Therapeutic Applications. New York, NY, Dekker, 1995, p 491
4.
Ogawa M:
Differentiation and proliferation of human hematopoietic stem cells.
Blood
81:2844,
1993[Abstract/Free Full Text]
5.
Meierhoff G,
Dehnel U,
Gruss HJ,
Rosnet O,
Birnbaum D,
Quentmeier H,
Dirks W,
Drexler HG:
Expression of FLT3 receptor and FLT3 ligand in human leukemia-lymphoma cell lines.
Leukemia
9:1368,
1995[Medline]
[Order article via Infotrieve]
6.
Ogawa M,
Matsuzaki Y,
Nishikawa SI,
Hayashi SI,
Kunisada T,
Sudo T,
Kina T,
Nakauchi H,
Nishikawa SI:
Expression and function of c-kit in hematopoietic progenitor cells.
J Exp Med
174:63,
1991[Abstract/Free Full Text]
7.
Kobayashi M,
Laver JH,
Kato T,
Miyazaki H,
Ogawa M:
Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with Steel factor and/or interleukin 3.
Blood
88:429,
1996[Abstract/Free Full Text]
8. Tsukamoto AS, Chen BP, Hoffman R, Uchida N, DiGiusto DL, Weissman IL, Baum CM: Phenotypic and functional analysis of hematopoietic stem cells in mouse and human, in Levitt D, Mertelsmann R (eds): Hematopoietic Stem Cells, Biology and Therapeutic Applications. New York, NY, Dekker, 1995, p 85
9.
Krause DS,
Fackler MJ,
Civin CI,
May WS:
CD34: Structure, biology, and clinical utility.
Blood
87:1,
1996[Free Full Text]
10. Wunder E, Sovalat H, Henon PR, Serke S: Hematopoietic Stem Cells. The Mulhouse Manual. Dayton OH, AlphaMed, 1993
11.
Auditore-Hargreaves K,
Heimfeld S,
Berenson RJ:
Selection and transplantation of hematopoietic stem and progenitor cells.
Bioconjugate Chem
5:287,
1994[Medline]
[Order article via Infotrieve]
12.
Fina L,
Molgaard HV,
Robertson D,
Bradley NJ,
Monaghan P,
Delia D,
Sutherland DR,
Baker MA,
Greaves MF:
Expression of the CD34 gene in vascular endothelial cells.
Blood
75:2417,
1990[Abstract/Free Full Text]
13.
Brown J,
Greaves MF,
Molgaard HV:
The gene encoding the stem cell antigen CD34 is conserved in mouse and expressed in hemopoietic progenitor cell lines, brain, and embryonic fibroblasts.
Int Immunol
3:175,
1991[Abstract/Free Full Text]
14.
Civin CI,
Banquerigo ML,
Strauss LC,
Loken MR:
Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10 positive progenitor cells in normal human bone marrow.
Exp Hematol
15:10,
1987[Medline]
[Order article via Infotrieve]
15.
Sutherland HJ,
Eaves CJ,
Evase AC,
Dragowska W,
Landsdorp PM:
Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro.
Blood
74:1563,
1989[Abstract/Free Full Text]
16.
Leary AG,
Ogawa M:
Blast cell colony assay for umbilical cord blood and adult marrow progenitors.
Blood
69:953,
1987[Abstract/Free Full Text]
17.
DiGiusto D,
Chen S,
Combs J,
Webb S,
Namikawa R,
Tsukamoto A,
Chen BP,
Galy AHM:
Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34.
Blood
84:421,
1994[Abstract/Free Full Text]
18.
Murray L,
Chen B,
Galy A,
Chen S,
Tushinski R,
Uchida N,
Negrin R,
Tricot G,
Jagannath S,
Vesole D,
Barlogie B,
Hoffman R,
Tsukamoto A:
Enrichment of human hematopoietic stem cell activity in the CD34+ Thy-1+Lin- subpopulation from mobilized peripheral blood.
Blood
85:368,
1995[Abstract/Free Full Text]
19.
Terstappen LWMM,
Huang S,
Safford M,
Lansdorp PM,
Loken MR:
Sequential generations of hematopoietic colonies derived from single non lineage-committed CD34+CD38- progenitor cells.
Blood
77:1218,
1991[Abstract/Free Full Text]
20.
Terstappen LWMM,
Huang S:
Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38- hematopoietic stem cells.
Blood
83:1515,
1994[Abstract/Free Full Text]
21.
Gunji Y,
Nakamura M,
Osawa H,
Nagayoshi K,
Nakauchi H,
Miura Y,
Yanagisawa M,
Suda T:
Human primitive hematopoietic progenitor cells are more enriched in KITlow cells than in KIThigh cells.
Blood
82:3283,
1993[Abstract/Free Full Text]
22.
Hashiyama M,
Iwama A,
Ohshiro K,
Kurozumi K,
Yasunaga K,
Shimizu Y,
Masuho Y,
Matsuda I,
Yamaguchi N,
Suda T:
Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells.
Blood
87:93,
1996[Abstract/Free Full Text]
23.
Batard P,
Sansilvestri P,
Scheinecker C,
Knapp W,
Debili N,
Vainchenker W,
Bühring HJ,
Monier MN,
Kukk E,
Partanen J,
Matikainen MT,
Alitalo R,
Hatzfeld J,
Alitalo K:
The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells.
Blood
87:2212,
1996[Abstract/Free Full Text]
24. Recktenwald DJ, Waller EK: Flow cytometric analysis, in Morstyn G, Sheridan W (eds): Cell Therapy, Stem Cell Transplantation, Gene Therapy and Cellular Immunotherapy. New York, NY, Cambridge University Press, 1996, p 75
25.
Fritsch G,
Buchinger P,
Printz D,
Fink M,
Mann G,
Peters C,
Wagner T,
Adler A,
Gadner H:
Rapid discrimination of early CD34+ myeloid progenitors using CD45RA analysis.
Blood
81:2301,
1993[Abstract/Free Full Text]
26.
Olweus J,
Terstappen WMM,
Thompson PA,
Lund-Johanssen F:
Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells.
Blood
88:1594,
1996[Abstract/Free Full Text]
27.
Baum CM,
Weissman IL,
Tsukamoto AS,
Buckle AM,
Peault B:
Isolation of a candidate human hematopoietic stem cell population.
Proc Natl Acad Sci USA
89:2804,
1992[Abstract/Free Full Text]
28. Boyum A: Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 21:77, 1968 (suppl 97)
29. Miltenyi S, Guth S, Radbruch A, Pflüger E, Thiel A: Isolation of CD34+ hematopoietic progenitor cells by high-gradient magnetic cell sorting (MACS), in Wunder E, Sovalat H, Hénon PR, Serke S (eds): Hematopoietic Stem Cells, The Mulhouse Manual. Dayton, OH, AlphaMed, 1994, p 201
30.
Köhler G,
Milstein C:
Continuous cultures of fused cells secreting antibody of predefined specificity.
Nature
256:495,
1975[Medline]
[Order article via Infotrieve]
31. Buck DW, Larrick JW, Raubitschek A, Truitt KE, Senyk G, Wang J, Dyer BJ: Production of human monoclonal antibodies, in Kennett RH, Bechtol KB, McKearn TJ (eds): Monoclonal Antibodies and Functional Cell Lines, New York, NY, Plenum, 1984, p 275
32.
Bjerknes R:
Flow cytometric assay for combined measurement of phagocytosis and intracellular killing of Candida albicans.
J Immunol Methods
72:229,
1984[Medline]
[Order article via Infotrieve]
33. Gagnon P: Protein A affinity purification, in Purification Tools for Monoclonal Antibodies. Tucson, AZ, Validated Biosystems Inc, 1996, p 158
34. Wofsy L, Henry C, Kimura J, North J: Modification and use of antibodies to label cell surface antigens, in Mishell BB, Shiigi SM (eds): Selected Methods in Cellular Immunology. San Francisco, CA, Freeman, 1980, p 294
35. Hardy RR: Purification and coupling of fluorescent proteins for use in flow cytometry, in Weir DM, Herzenberg LA, Blackwell CC, Herzenberg LA (eds): Handbook of Experimental Immunology. Oxford, UK, Blackwell Scientific, 1986, p 31
36. Leary AG, Ogawa M: Assay for human blast cell colonies, in Freshney RI, Pragnell IB, Freshney MG (eds): Culture of Hematopoietic Cells. New York, NY, Wiley-Liss, 1994, p 55
37.
Leary AG,
Yang Y-C,
Clark SC,
Gasson JC,
Golde DW,
Ogawa M:
Recombinant gibbon interleukin-3 (IL-3) supports formation of human multilineage colonies and blast cell colonies culture: Comparison with recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF).
Blood
70:11343,
1987
38.
Flake AW,
Harrison MR,
Adzick NS,
Zanjani ED:
Transplantation of fetal hematopoietic cells in utero: The creation of hematopoietic chimeras.
Science
233:776,
1986[Abstract/Free Full Text]
39.
Zanjani ED,
Flake AW,
Rice H,
Hedrick M,
Tavassoli M:
Long-term repopulating ability of xenogeneic transplanted human fetal liver hematopoietic stem cells (HSC) in sheep.
J Clin Invest
93:1051,
1994
40.
Zanjani ED,
Srour FR,
Hoffman R:
Retention of long-term repopulating ability of xenogeneic transplanted purified adult human stem cells in sheep.
J Clin Lab Med
126:24,
1995[Medline]
[Order article via Infotrieve]
41.
Miraglia S,
Godfrey WG,
Yin AH,
Atkins K,
Warnke R,
Holden JT,
Bray RA,
Waller EK,
Buck DW:
A novel 5-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning.
Blood
90:5013,
1997[Abstract/Free Full Text]
42.
Waller EK,
Olweus J,
Lund-Johansen F,
Huang S,
Nguyen M,
Guo G,
Terstappen L:
The "common stem cell" hypothesis reevaluated: Human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors.
Blood
85:2422,
1994[Abstract/Free Full Text]
43.
Loken MR,
Shah VO,
Dattilio KL,
Civin CI:
Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development.
Blood
70:1316,
1987[Abstract/Free Full Text]
44.
Olweus J,
Lund-Johansen F,
Terstappen LWMM:
CD64/FcRI is a granulomonocytic lineage marker on CD34+ hematopoietic progenitor cells.
Blood
85:2402,
1994[Abstract/Free Full Text]
45.
Lansdorp PM,
Dragowska W:
Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow.
J Exp Med
175:1501,
1992[Abstract/Free Full Text]
46. Barclay AN, Birkeland ML, Beyers AD, Somoza C, Williams AF: The Leucocyte Antigen Facts Book. San Diego, CA, Academic, 1993
47. Schlossman S, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF: Leucocyte Typing, vol 5. New York, NY, Oxford University Press, 1995
48.
Civin CI,
Almeida-Porada G,
Le M-J,
Olweus J,
Terstappen LWMM,
Zanjani ED:
Sustained retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo.
Blood
88:4102,
1996[Abstract/Free Full Text]
49.
Zanjani ED,
Pallavicini MG,
Ascensao JL,
Flake AW,
Langlois RG,
Reitsma M,
MacKintosh FR,
Stutes D,
Harrison MR,
Tavassoli M:
Engraftment and long term expression of human fetal hematopoietic stem cells in sheep following transplantation in utero.
J Clin Invest
89:1178,
1992
50. Hill B, Rozler E, Liu G, Ramanathan R, Hoffman R, Chen B: Elicitation and characterization of monoclonal antibodies which bind to subsets of CD34+ but not to CD34- bone marrow cells. Blood 86:1948a, 1995 (abstr)
51.
Brooks PC,
Lin JM,
French DL,
Quigley JP:
Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis.
J Cell Biol
122:1351,
1993[Abstract/Free Full Text]
52.
Yuge K,
Nakajima M,
Uemura Y,
Miki H,
Uyama M,
Tsubura A:
Immunohistochemical features of the human retina and retinoblastoma.
Virchows Arch
426:571,
1995[Medline]
[Order article via Infotrieve]
53. McCarrick JW, Andrews PW: Embryonal carcinoma cells and embryonic stem cells as models for neuronal development and function, in Wood JN (ed): Neuronal Cell Lines, A Practical Approach. Oxford, UK, Oxford University, 1992, p 77
54.
Andrews PW,
Damjanoy J,
Simon D,
Banting GS,
Carlin C,
Dracopoli NC,
Fogh J:
Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tra-2 differentiation in vivo and in vitro.
Lab Invest
50:147,
1984[Medline]
[Order article via Infotrieve]
55.
Osawa M,
Hanada K,
Hamada H,
Nakauchi H:
Long-term lymphoproliferative reconstitution by a single CD34-low/negative hematopoietic stem cell.
Science
273:242,
1996[Abstract]
56.
Pertovaara L,
Tienari J,
Vainikka S,
Partanen J,
Saksela O,
Lehtonen E,
Alitalo K:
Modulation of fibroblast growth factor receptor expression and signalling during retinoic acid induced differentiation of Tera-2 teratocarcinoma cells.
Biochem Biophys Res Commun
191:149,
1993[Medline]
[Order article via Infotrieve]
57.
Larochelle A,
Vermoor J,
Hanenberg H,
Wang JCY,
Bhatia M,
Lapidot T,
Moritz T,
Murdoch B,
Xiao XL,
Kato I,
Williams DA,
Dick JE:
Identification of primitive hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy.
Nat Med
2:1329,
1996[Medline]
[Order article via Infotrieve]
58. To LB, Roberts MM, Rawling CM, Rowlings PA, Dyson PG, Rawling TP, Haylock DN, Juttner CA: Establishment of a clinical threshold cell dose: Correlation between CFU-GM and duration of aplasia, in Wunder E, Sovalat H, Hénon PR, Serke S (eds): Hematopoietic Stem Cells, The Mulhouse Manual. Dayton, OH, AlphaMed, 1995, p 15
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Ii, H. Nishimura, H. Sekiguchi, N. Kamei, A. Yokoyama, M. Horii, and T. Asahara
Concurrent Vasculogenesis and Neurogenesis From Adult Neural Stem Cells
Circ. Res.,
October 23, 2009;
105(9):
860 - 868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bertolini, L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti, G. Pratesi, A. Fabbri, F. Andriani, S. Tinelli, et al.
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment
PNAS,
September 22, 2009;
106(38):
16281 - 16286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rutella, G. Bonanno, A. Procoli, A. Mariotti, M. Corallo, M. G. Prisco, A. Eramo, C. Napoletano, D. Gallo, A. Perillo, et al.
Cells with Characteristics of Cancer Stem/Progenitor Cells Express the CD133 Antigen in Human Endometrial Tumors
Clin. Cancer Res.,
July 1, 2009;
15(13):
4299 - 4311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Wu, A. Chang, M. C. Smith, R. Won, X. Yin, S. M. Staugaitis, D. Agamanolis, G. J. Kidd, R. H. Miller, and B. D. Trapp
{beta}4 Tubulin Identifies a Primitive Cell Source for Oligodendrocytes in the Mammalian Brain
J. Neurosci.,
June 17, 2009;
29(24):
7649 - 7657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Yao, A. L. Firth, R. S. Sacks, A. Ogawa, W. R. Auger, P. F. Fedullo, M. M. Madani, G. Y. Lin, N. Sakakibara, P. A. Thistlethwaite, et al.
Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol,
June 1, 2009;
296(6):
L870 - L878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Capoccia, D. L. Robson, K. D. Levac, D. J. Maxwell, S. A. Hohm, M. J. Neelamkavil, G. I. Bell, A. Xenocostas, D. C. Link, D. Piwnica-Worms, et al.
Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity
Blood,
May 21, 2009;
113(21):
5340 - 5351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Chen, R. A.F. Dixon, L.-Y. Ke, and J. T. Willerson
Vascular Progenitor Cells in Diabetes Mellitus: Roles of Wnt Signaling and Negatively Charged Low-Density Lipoprotein
Circ. Res.,
May 8, 2009;
104(9):
1038 - 1040.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yanagisawa, I. Kadouchi, K. Yokomori, M. Hirose, M. Hakozaki, H. Hojo, K. Maeda, E. Kobayashi, and T. Murakami
Identification and Metastatic Potential of Tumor-Initiating Cells in Malignant Rhabdoid Tumor of the Kidney
Clin. Cancer Res.,
May 1, 2009;
15(9):
3014 - 3022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Leone, M. Valgimigli, M. B. Giannico, V. Zaccone, M. Perfetti, D. D'Amario, A. G. Rebuzzi, and F. Crea
From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells
Eur. Heart J.,
April 2, 2009;
30(8):
890 - 899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. V. Cox, P. Diamanti, R. S. Evely, P. R. Kearns, and A. Blair
Expression of CD133 on leukemia-initiating cells in childhood ALL
Blood,
April 2, 2009;
113(14):
3287 - 3296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.N. Rich and C.E. Eyler
Cancer Stem Cells in Brain Tumor Biology
Cold Spring Harb Symp Quant Biol,
March 27, 2009;
(2009)
sqb.2008.73.060v1.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. S. Bonder, W. Y. Sun, T. Matthews, C. Cassano, X. Li, H. S. Ramshaw, S. M. Pitson, A. F. Lopez, P. T. Coates, R. L. Proia, et al.
Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation
Blood,
February 26, 2009;
113(9):
2108 - 2117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zacchigna, H. Oh, M. Wilsch-Brauninger, E. Missol-Kolka, J. Jaszai, S. Jansen, N. Tanimoto, F. Tonagel, M. Seeliger, W. B. Huttner, et al.
Loss of the Cholesterol-Binding Protein Prominin-1/CD133 Causes Disk Dysmorphogenesis and Photoreceptor Degeneration
J. Neurosci.,
February 18, 2009;
29(7):
2297 - 2308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Jiang, B. J. Collins, N. Jin, D. N. Watkins, M. V. Brock, W. Matsui, B. D. Nelkin, and D. W. Ball
Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer
Cancer Res.,
February 1, 2009;
69(3):
845 - 854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Karbanova, E. Missol-Kolka, A.-V. Fonseca, C. Lorra, P. Janich, H. Hollerova, J. Jaszai, J. Ehrmann, Z. Kolar, C. Liebers, et al.
The Stem Cell Marker CD133 (Prominin-1) Is Expressed in Various Human Glandular Epithelia
J. Histochem. Cytochem.,
November 1, 2008;
56(11):
977 - 993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Madonna and R. De Caterina
In vitro neovasculogenic potential of resident adipose tissue precursors
Am J Physiol Cell Physiol,
November 1, 2008;
295(5):
C1271 - C1280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Yi, H.-C. Tsai, S. C. Glockner, S. Lin, J. E. Ohm, H. Easwaran, C. D. James, J. F. Costello, G. Riggins, C. G. Eberhart, et al.
Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors
Cancer Res.,
October 1, 2008;
68(19):
8094 - 8103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Li, Y. Han, W. Pang, C. Li, X. Xie, J. Y.-J. Shyy, and Y. Zhu
AMP-Activated Protein Kinase Promotes the Differentiation of Endothelial Progenitor Cells
Arterioscler Thromb Vasc Biol,
October 1, 2008;
28(10):
1789 - 1795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suriano, D. Chaudhuri, R. S. Johnson, E. Lambers, B. T. Ashok, R. Kishore, and R. K. Tiwari
17{beta}-Estradiol Mobilizes Bone Marrow-Derived Endothelial Progenitor Cells to Tumors
Cancer Res.,
August 1, 2008;
68(15):
6038 - 6042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Xiao, Y. Ye, K. Yearsley, S. Jones, and S. H. Barsky
The Lymphovascular Embolus of Inflammatory Breast Cancer Expresses a Stem Cell-Like Phenotype
Am. J. Pathol.,
August 1, 2008;
173(2):
561 - 574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P.W. Rouhl, R. J. van Oostenbrugge, J. Damoiseaux, J.-W. C. Tervaert, and J. Lodder
Endothelial Progenitor Cell Research in Stroke: A Potential Shift in Pathophysiological and Therapeutical Concepts
Stroke,
July 1, 2008;
39(7):
2158 - 2165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Dirks
Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer
J. Clin. Oncol.,
June 10, 2008;
26(17):
2916 - 2924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.E. Schwab, P. Hutchinson, and C.E. Gargett
Identification of surface markers for prospective isolation of human endometrial stromal colony-forming cells
Hum. Reprod.,
April 1, 2008;
23(4):
934 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Shantsila, T. Watson, H.-F. Tse, and G. Y.H. Lip
New insights on endothelial progenitor cell subpopulations and their angiogenic properties.
J. Am. Coll. Cardiol.,
February 12, 2008;
51(6):
669 - 671.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B Dirks
Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells
Phil Trans R Soc B,
January 12, 2008;
363(1489):
139 - 152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zeppernick, R. Ahmadi, B. Campos, C. Dictus, B. M. Helmke, N. Becker, P. Lichter, A. Unterberg, B. Radlwimmer, and C. C. Herold-Mende
Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients
Clin. Cancer Res.,
January 1, 2008;
14(1):
123 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. I. Chang, S. A. Loh, D. J. Ceradini, E. I. Chang, S.-e Lin, N. Bastidas, S. Aarabi, D. A. Chan, M. L. Freedman, A. J. Giaccia, et al.
Age Decreases Endothelial Progenitor Cell Recruitment Through Decreases in Hypoxia-Inducible Factor 1{alpha} Stabilization During Ischemia
Circulation,
December 11, 2007;
116(24):
2818 - 2829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-J. Liao, C. C. Zhang, B. Zhou, D. B. Zimonjic, S. A. Mani, M. Kaba, A. Gifford, F. Reinhardt, N. C. Popescu, W. Guo, et al.
Enrichment of a Population of Mammary Gland Cells that Form Mammospheres and Have In vivo Repopulating Activity
Cancer Res.,
September 1, 2007;
67(17):
8131 - 8138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yanagisawa and R. K Yu
The expression and functions of glycoconjugates in neural stem cells
Glycobiology,
July 1, 2007;
17(7):
57R - 74R.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Timmermans, F. Van Hauwermeiren, M. De Smedt, R. Raedt, F. Plasschaert, M. L. De Buyzere, T. C. Gillebert, J. Plum, and B. Vandekerckhove
Endothelial Outgrowth Cells Are Not Derived From CD133+ Cells or CD45+ Hematopoietic Precursors
Arterioscler Thromb Vasc Biol,
July 1, 2007;
27(7):
1572 - 1579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nagano, T. Yamashita, H. Hamada, K. Ohneda, K.-i. Kimura, T. Nakagawa, M. Shibuya, H. Yoshikawa, and O. Ohneda
Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood
Blood,
July 1, 2007;
110(1):
151 - 160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. V. Pfenninger, T. Roschupkina, F. Hertwig, D. Kottwitz, E. Englund, J. Bengzon, S. E. Jacobsen, and U. A. Nuber
CD133 Is Not Present on Neurogenic Astrocytes in the Adult Subventricular Zone, but on Embryonic Neural Stem Cells, Ependymal Cells, and Glioblastoma Cells
Cancer Res.,
June 15, 2007;
67(12):
5727 - 5736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Balasubramaniam, C. F. Mervis, A. M. Maxey, N. E. Markham, and S. H. Abman
Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia
Am J Physiol Lung Cell Mol Physiol,
May 1, 2007;
292(5):
L1073 - L1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Miki, B. Furusato, H. Li, Y. Gu, H. Takahashi, S. Egawa, I. A. Sesterhenn, D. G. McLeod, S. Srivastava, and J. S. Rhim
Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT-Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens
Cancer Res.,
April 1, 2007;
67(7):
3153 - 3161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Casamassimi, M. L. Balestrieri, C. Fiorito, C. Schiano, C. Maione, R. Rossiello, V. Grimaldi, V. Del Giudice, C. Balestrieri, B. Farzati, et al.
Comparison Between Total Endothelial Progenitor Cell Isolation Versus Enriched Cd133+ Culture
J. Biochem.,
April 1, 2007;
141(4):
503 - 511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fazel
Bone marrow cell therapy for heart disease: A few good men and women wanted
J. Thorac. Cardiovasc. Surg.,
March 1, 2007;
133(3):
599 - 600.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tan, H. Shao, D. Eton, Z. Yang, L. Alonso-Diaz, H. Zhang, A. Schulick, A. S. Livingstone, and H. Yu
Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor
Cardiovasc Res,
March 1, 2007;
73(4):
823 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Dubreuil, A.-M. Marzesco, D. Corbeil, W. B. Huttner, and M. Wilsch-Brauninger
Midbody and primary cilium of neural progenitors release extracellular membrane particles enriched in the stem cell marker prominin-1
J. Cell Biol.,
February 12, 2007;
176(4):
483 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Perrella, P Brusini, R Spelat, P Hossain, A Hopkinson, and H S Dua
Expression of haematopoietic stem cell markers, CD133 and CD34 on human corneal keratocytes
Br J Ophthalmol,
January 1, 2007;
91(1):
94 - 99.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bruno, B. Bussolati, C. Grange, F. Collino, M. E. Graziano, U. Ferrando, and G. Camussi
CD133+ Renal Progenitor Cells Contribute to Tumor Angiogenesis
Am. J. Pathol.,
December 1, 2006;
169(6):
2223 - 2235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Y. Frank, A. T. Kho, T. Schatton, G. F. Murphy, M. J. Molloy, Q. Zhan, M. F. Ramoni, M. H. Frank, I. S. Kohane, and E. Gussoni
Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin
J. Cell Biol.,
October 9, 2006;
175(1):
99 - 110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mehra, M. Penning, J. Maas, L. V. Beerepoot, N. van Daal, C. H. van Gils, R. H. Giles, and E. E. Voest
Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases.
Clin. Cancer Res.,
August 15, 2006;
12(16):
4859 - 4866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Fan, W. Matsui, L. Khaki, D. Stearns, J. Chun, Y.-M. Li, and C. G. Eberhart
Notch Pathway Inhibition Depletes Stem-like Cells and Blocks Engraftment in Embryonal Brain Tumors.
Cancer Res.,
August 1, 2006;
66(15):
7445 - 7452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Boyle, S. P. Schulman, and J. M. Hare
Stem Cell Therapy for Cardiac Repair: Ready for the Next Step
Circulation,
July 25, 2006;
114(4):
339 - 352.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ma, Y. Ladilov, J. M. Moebius, L. Ong, C. Piechaczek, A. David, A. Kaminski, Y.-H. Choi, W. Li, D. Egger, et al.
Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells
Cardiovasc Res,
July 1, 2006;
71(1):
158 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Sheridan, D. Rice, P. S. Hiscott, D. Wong, and D. L. Kent
The Presence of AC133-Positive Cells Suggests a Possible Role of Endothelial Progenitor Cells in the Formation of Choroidal Neovascularization.
Invest. Ophthalmol. Vis. Sci.,
April 1, 2006;
47(4):
1642 - 1645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. I. Peinado, J. Ramirez, J. Roca, R. Rodriguez-Roisin, and J. A. Barbera
Identification of Vascular Progenitor Cells in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Cell Mol. Biol.,
March 1, 2006;
34(3):
257 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Giebel, T. Zhang, J. Beckmann, J. Spanholtz, P. Wernet, A. D. Ho, and M. Punzel
Primitive human hematopoietic cells give rise to differentially specified daughter cells upon their initial cell division
Blood,
March 1, 2006;
107(5):
2146 - 2152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Hess, L. Wirthlin, T. P. Craft, P. E. Herrbrich, S. A. Hohm, R. Lahey, W. C. Eades, M. H. Creer, and J. A. Nolta
Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells
Blood,
March 1, 2006;
107(5):
2162 - 2169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Muguruma, T. Yahata, H. Miyatake, T. Sato, T. Uno, J. Itoh, S. Kato, M. Ito, T. Hotta, and K. Ando
Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment
Blood,
March 1, 2006;
107(5):
1878 - 1887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Hill, M. A. Syed, A. E. Arai, T. M. Powell, J. D. Paul, G. Zalos, E. J. Read, H. M. Khuu, S. F. Leitman, M. Horne, et al.
Outcomes and Risks of Granulocyte Colony-Stimulating Factor in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1643 - 1648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Elsheikh, M. Uzunel, Z. He, J. Holgersson, G. Nowak, and S. Sumitran-Holgersson
Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity
Blood,
October 1, 2005;
106(7):
2347 - 2355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, N. Hersmus, V. V. Duppen, P. Caesens, C. Denef, and H. Vankelecom
The Adult Pituitary Contains a Cell Population Displaying Stem/Progenitor Cell and Early Embryonic Characteristics
Endocrinology,
September 1, 2005;
146(9):
3985 - 3998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. J. Woo, T. J. Grand, M. F. Berry, P. Atluri, M. A. Moise, V. M. Hsu, J. Cohen, O. Fisher, J. Burdick, M. Taylor, et al.
Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy
J. Thorac. Cardiovasc. Surg.,
August 1, 2005;
130(2):
321 - 329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Bauer, R. J. Bauer, and O. C. Velazquez
Angiogenesis, Vasculogenesis, and Induction of Healing in Chronic Wounds
Vascular and Endovascular Surgery,
July 1, 2005;
39(4):
293 - 306.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A.-M. Marzesco, P. Janich, M. Wilsch-Brauninger, V. Dubreuil, K. Langenfeld, D. Corbeil, and W. B. Huttner
Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells
J. Cell Sci.,
July 1, 2005;
118(13):
2849 - 2858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Feller, M. A. van der Pol, T. Waaijman, G. W.D. Weijers, G. Westra, G. J. Ossenkoppele, and G. J. Schuurhuis
Immunologic Purging of Autologous Peripheral Blood Stem Cell Products Based on CD34 and CD133 Expression Can Be Effectively and Safely Applied in Half of the Acute Myeloid Leukemia Patients
Clin. Cancer Res.,
July 1, 2005;
11(13):
4793 - 4801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. K. Haider and M. Ashraf
Bone marrow stem cell transplantation for cardiac repair
Am J Physiol Heart Circ Physiol,
June 1, 2005;
288(6):
H2557 - H2567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Zhang and H. F. Lodish
Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion
Blood,
June 1, 2005;
105(11):
4314 - 4320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Y. Frank, A. Margaryan, Y. Huang, T. Schatton, A. M. Waaga-Gasser, M. Gasser, M. H. Sayegh, W. Sadee, and M. H. Frank
ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma
Cancer Res.,
May 15, 2005;
65(10):
4320 - 4333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Shmelkov, S. Meeus, N. Moussazadeh, P. Kermani, W. K. Rashbaum, S. Y. Rabbany, M. A. Hanson, W. J. Lane, R. St. Clair, K. A. Walsh, et al.
Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133+ Stem Cells Into Angiomyogenic Tissue
Circulation,
March 8, 2005;
111(9):
1175 - 1183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hieronymus, T. C. Gust, R. D. Kirsch, T. Jorgas, G. Blendinger, M. Goncharenko, K. Supplitt, S. Rose-John, A. M. Muller, and M. Zenke
Progressive and Controlled Development of Mouse Dendritic Cells from Flt3+CD11b+ Progenitors In Vitro
J. Immunol.,
March 1, 2005;
174(5):
2552 - 2562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. De Felice, C. Tatarelli, M. G. Mascolo, C. Gregorj, F. Agostini, R. Fiorini, V. Gelmetti, S. Pascale, F. Padula, M. T. Petrucci, et al.
Histone Deacetylase Inhibitor Valproic Acid Enhances the Cytokine-Induced Expansion of Human Hematopoietic Stem Cells
Cancer Res.,
February 15, 2005;
65(4):
1505 - 1513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bussolati, S. Bruno, C. Grange, S. Buttiglieri, M. C. Deregibus, D. Cantino, and G. Camussi
Isolation of Renal Progenitor Cells from Adult Human Kidney
Am. J. Pathol.,
February 1, 2005;
166(2):
545 - 555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Powell, J. D. Paul, J. M. Hill, M. Thompson, M. Benjamin, M. Rodrigo, J. P. McCoy, E. J. Read, H. M. Khuu, S. F. Leitman, et al.
Granulocyte Colony-Stimulating Factor Mobilizes Functional Endothelial Progenitor Cells in Patients With Coronary Artery Disease
Arterioscler Thromb Vasc Biol,
February 1, 2005;
25(2):
296 - 301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Davani, F. Deschaseaux, D. Chalmers, P. Tiberghien, and J.-P. Kantelip
Can stem cells mend a broken heart?
Cardiovasc Res,
February 1, 2005;
65(2):
305 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Vodyanik, J. A. Bork, J. A. Thomson, and I. I. Slukvin
Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential
Blood,
January 15, 2005;
105(2):
617 - 626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Massa, V. Rosti, M. Ferrario, R. Campanelli, I. Ramajoli, R. Rosso, G. M. De Ferrari, M. Ferlini, L. Goffredo, A. Bertoletti, et al.
Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction
Blood,
January 1, 2005;
105(1):
199 - 206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I B Resnick and S Slavin
Lessons from bone marrow transplantation for a victim of a radiological accident with acute radiation syndrome
Br. J. Radiol.,
January 1, 2005;
Supplement_27(1):
21 - 25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nowak, A. Karrar, C. Holmen, S. Nava, M. Uzunel, K. Hultenby, and S. Sumitran-Holgersson
Expression of Vascular Endothelial Growth Factor Receptor-2 or Tie-2 on Peripheral Blood Cells Defines Functionally Competent Cell Populations Capable of Reendothelialization
Circulation,
December 14, 2004;
110(24):
3699 - 3707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Giebel, D. Corbeil, J. Beckmann, J. Hohn, D. Freund, K. Giesen, J. Fischer, G. Kogler, and P. Wernet
Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells
Blood,
October 15, 2004;
104(8):
2332 - 2338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Almeida-Porada, C. D. Porada, J. Chamberlain, A. Torabi, and E. D. Zanjani
Formation of human hepatocytes by human hematopoietic stem cells in sheep
Blood,
October 15, 2004;
104(8):
2582 - 2590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Hess, T. E. Meyerrose, L. Wirthlin, T. P. Craft, P. E. Herrbrich, M. H. Creer, and J. A. Nolta
Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity
Blood,
September 15, 2004;
104(6):
1648 - 1655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W Hilbe, S Dirnhofer, F Oberwasserlechner, T Schmid, E Gunsilius, G Hilbe, E Woll, and C M Kahler
CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer
J. Clin. Pathol.,
September 1, 2004;
57(9):
965 - 969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Fargeas, A. Joester, E. Missol-Kolka, A. Hellwig, W. B. Huttner, and D. Corbeil
Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis
J. Cell Sci.,
August 15, 2004;
117(18):
4301 - 4311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Wu, E. Rabkin-Aikawa, K. J. Guleserian, T. E. Perry, Y. Masuda, F. W. H. Sutherland, F. J. Schoen, J. E. Mayer Jr., and J. Bischoff
Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells
Am J Physiol Heart Circ Physiol,
August 1, 2004;
287(2):
H480 - H487.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wagner, A. Ansorge, U. Wirkner, V. Eckstein, C. Schwager, J. Blake, K. Miesala, J. Selig, R. Saffrich, W. Ansorge, et al.
Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis
Blood,
August 1, 2004;
104(3):
675 - 686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Miranville, C. Heeschen, C. Sengenes, C.A. Curat, R. Busse, and A. Bouloumie
Improvement of Postnatal Neovascularization by Human Adipose Tissue-Derived Stem Cells
Circulation,
July 20, 2004;
110(3):
349 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Richardson, C. N. Robson, S. H. Lang, D. E. Neal, N. J. Maitland, and A. T. Collins
CD133, a novel marker for human prostatic epithelial stem cells
J. Cell Sci.,
July 15, 2004;
117(16):
3539 - 3545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Shmelkov, L. Jun, R. St Clair, D. McGarrigle, C. A. Derderian, J. K. Usenko, C. Costa, F. Zhang, X. Guo, and S. Rafii
Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133
Blood,
March 15, 2004;
103(6):
2055 - 2061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Y. Frank, S. S. Pendse, P. H. Lapchak, A. Margaryan, D. Shlain, C. Doeing, M. H. Sayegh, and M. H. Frank
Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, a Novel Human ATP-binding Cassette Transporter
J. Biol. Chem.,
November 21, 2003;
278(47):
47156 - 47165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yamamoto, T. Takahashi, T. Asahara, N. Ohura, T. Sokabe, A. Kamiya, and J. Ando
Proliferation, differentiation, and tube formation by endothelial progenitor cells in response to shear stress
J Appl Physiol,
November 1, 2003;
95(5):
2081 - 2088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins, J. Squire, and P. B. Dirks
Identification of a Cancer Stem Cell in Human Brain Tumors
Cancer Res.,
September 15, 2003;
63(18):
5821 - 5828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. N. Schwartz, B. A. Vance, B. M. Levine, M. Fukazawa, W. G. Telford, D. Cesar, M. Hellerstein, and R. E. Gress
Proliferation kinetics of subpopulations of human marrow cells determined by quantifying in vivo incorporation of [2H2]-glucose into DNA of S-phase cells
Blood,
September 15, 2003;
102(6):
2068 - 2073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hristov, W. Erl, and P. C. Weber
Endothelial Progenitor Cells: Mobilization, Differentiation, and Homing
Arterioscler Thromb Vasc Biol,
July 1, 2003;
23(7):
1185 - 1189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Szmitko, P. W.M. Fedak, R. D. Weisel, D. J. Stewart, M. J.B. Kutryk, and S. Verma
Endothelial Progenitor Cells: New Hope for a Broken Heart
Circulation,
June 24, 2003;
107(24):
3093 - 3100.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Angelastro, T. N. Ignatova, V. G. Kukekov, D. A. Steindler, G. B. Stengren, C. Mendelsohn, and L. A. Greene
Regulated Expression of ATF5 Is Required for the Progression of Neural Progenitor Cells to Neurons
J. Neurosci.,
June 1, 2003;
23(11):
4590 - 4600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Masuda and T. Asahara
Post-natal endothelial progenitor cells for neovascularization in tissue regeneration
Cardiovasc Res,
May 1, 2003;
58(2):
390 - 398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Eggermann, S. Kliche, G. Jarmy, K. Hoffmann, U. Mayr-Beyrle, K.-M. Debatin, J. Waltenberger, and C. Beltinger
Endothelial progenitor cell culture and differentiation in vitro: a methodological comparison using human umbilical cord blood
Cardiovasc Res,
May 1, 2003;
58(2):
478 - 486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Nakul-Aquaronne, J. Bayle, and C. Frelin
Coexpression of endothelial markers and CD14 by cytokine mobilized CD34+ cells under angiogenic stimulation
Cardiovasc Res,
March 1, 2003;
57(3):
816 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Fargeas, M. Florek, W. B. Huttner, and D. Corbeil
Characterization of Prominin-2, a New Member of the Prominin Family of Pentaspan Membrane Glycoproteins
J. Biol. Chem.,
February 28, 2003;
278(10):
8586 - 8596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kuci, J. T. Wessels, H.-J. Buhring, K. Schilbach, M. Schumm, G. Seitz, J. Loffler, P. Bader, P. G. Schlegel, D. Niethammer, et al.
Identification of a novel class of human adherent CD34- stem cells that give rise to SCID-repopulating cells
Blood,
February 1, 2003;
101(3):
869 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Cottler-Fox, T. Lapidot, I. Petit, O. Kollet, J. F. DiPersio, D. Link, and S. Devine
Stem Cell Mobilization
Hematology,
January 1, 2003;
2003(1):
419 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Salven, S. Mustjoki, R. Alitalo, K. Alitalo, and S. Rafii
VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells
Blood,
January 1, 2003;
101(1):
168 - 172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Burger, S. Coetzee, W. L. McKeehan, M. Kan, P. Cook, Y. Fan, T. Suda, R. P. Hebbel, N. Novitzky, W. A. Muller, et al.
Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells
Blood,
November 15, 2002;
100(10):
3527 - 3535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract